List view / Grid view
In this article, Patrick Kendall, Scientific Advisor for Artelo Biosciences, outlines why future treatment of cancer anorexia-cachexia syndrome may lie with drugs in development offering a mechanistic approach.
Scientists captured more than 1,000 hours of brain recordings from obsessive compulsive disorder (OCD) patients and uncovered candidate neurological signatures.
The new nanotechnology left six of 10 mice with lymphoma tumour-free and was effective in melanoma when combined with existing drugs.
The self-assembling, nanomatrix gel may represent the first effective therapy to promote healthy arteriovenous fistula (AVF) maturation in kidney disease patients.
Gallic acid was found to decrease arthritis inflammation markers and improve the production of desired proteins in arthritic knee cells.
Researchers developed a platform that can rapidly screen thousands of compounds to identify potential antiviral drugs to treat coronaviruses.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
A new study provides an in-depth review on the designs and applications of morphology-transformable nanoparticles to improve cancer therapies.
All mice infected with anthrax spores were completely protected after treatment with a pegylated enzyme known as PEG-CapD-CPS334C.
Researchers developed a patient-specific zebrafish model for arrhythmogenic cardiomyopathy (ACM) and tested istaroxime as a potential therapeutic.
The new nanoparticle uses a peptide to target the vascular cell adhesion molecule 1 and reduced the size of vascular lesions in a mouse study.
The new study used sequence clustering analysis to identify four subgroups of COVID-19 to help match patients to specific treatments.
Scientists identify a drug candidate to minimise erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
Everest Medicines and Providence Therapeutics have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.
A novel antiviral drug called thapsigargin (TG) blocked COVID-19 infection in cells, including all new variants, in a pre-clinical study.
